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Purpose	While patient engagement is becoming more customary in developing health products, its monitoring
and evaluation to understand processes and enhance impact are challenging. This article describes
a patient engagement monitoring and evaluation (PEME) framework, co-created and tailored to the
context of community advisory boards (CABs) for rare diseases in Europe. It can be used to stimulate
learning and evaluate impacts of engagement activities.
Methods	A participatory approach was used in which data collection and analysis were iterative. The process
was based on the principles of interactive learning and action and guided by the PEME framework.
Data were collected via document analysis, reflection sessions, a questionnaire, and a workshop.
Results 	The tailored framework consists of a theory of change model with metrics explaining how CABs can
reach their objectives. Of 61 identified metrics, 17 metrics for monitoring the patient engagement
process and short-term outcomes were selected, and a “menu” for evaluating long-term impacts was
created. Example metrics include “Industry representatives’ understanding of patients’ unmet needs;”
“Feeling of trust between stakeholders;” and “Feeling of preparedness.” “Alignment of research
programs with patients’ needs” was the highest-ranked metric for long-term impact.
Conclusions	Findings suggest that process and short-term outcome metrics could be standardized across CABs,
whereas long-term impact metrics may need to be tailored to the collaboration from a proposed menu.
Accordingly, we recommend that others adapt and refine the PEME framework as appropriate. The
next steps include implementing and testing the evaluation framework to stimulate learning and share
impacts. (J Patient Cent Res Rev. 2022;9:46-57.)
Keywords

patient engagement; patient participation; rare diseases; program evaluation; drug development

P

atient engagement is increasingly integrated along
the life cycle of research and development (R&D)
for health products (ie, medicines, technologies and
services) as an essential element in moving toward a more
patient-centered R&D system.1-3 Patient engagement
is defined as “the active, meaningful, and collaborative
interaction between patients and researchers across all
stages” of health product R&D, “where decision-making is
Corresponding author: Sevgi E. Fruytier,
Athena Institute, Vrije Universiteit Amsterdam, de Boelelaan
1087, 1081 HV Amsterdam, Netherlands (s.e.fruytier@vu.nl)
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guided by patients’ contributions as partners, recognising
their specific experiences, values, and expertise.”4 Such
interactions have rapidly increased in the last decade,
taking many shapes and forms.1,5 However, little is
known about how these interactions affect health product
R&D processes and their stakeholders.6,7 This knowledge
gap makes it difficult to understand best practices and
the value of patient engagement, increasing the risk
of tokenism and hindering successful embedding of
practices in R&D processes.8,9 The need for monitoring
and evaluation (M&E) to elucidate whether, how, and
why the objectives of patient engagement are achieved
has been repeatedly articulated.7,10
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Despite the need, M&E of patient engagement initiatives
in health product R&D is scarce, and current evidence
is often considered anecdotal.6,10,11 Previous literature
reviews discussing M&E tools and frameworks report
concerns regarding their scientific rigor, lack of cocreation and impact assessment, and limited transferability
to other settings.12-14 Various challenges underlie these
limitations. First, patient engagement initiatives are
highly contextualized and relational in nature, and it often
takes years before impact can be seen.15,16 Consequently,
many different factors influence the causal chains leading
to impact, impeding the attribution of causality and the
generalization of conclusions.10 Moreover, stakeholders
have different needs and priorities, and therefore views
vary on what constitutes successful patient engagement.7,14
Partly because of this, there is no consensus on
relevant evaluation criteria and tools. While some seek
standardization across the field to enable generalization
and comparison,1,7,17 others argue that M&E frameworks
and tools provide more meaningful insights when tailored
to the initiative and co-created with those involved.12,14,18
This article presents a tailored M&E framework for
community advisory boards (CABs) participating in the
European Organisation for Rare Diseases (EURORDIS)
program (collectively known as EuroCAB).19 CABs are
autonomous groups of patient representatives (ie, CAB
members), nominated and selected by their community,
who offer their expertise to public and private
sponsors of research in their disease area (mainly, the
biopharmaceutical industry) through advisory meetings.20
They aim to align clinical research to community needs and
realities.21 EuroCAB was established to provide training
and support for CABs in the field of rare diseases.19 CAB
members and industry representatives expressed the need
for evaluation to gain a deeper understanding of the CAB
processes and outcomes in order to identify strategies to
enhance and demonstrate their impact. Accordingly, the
objective of this study is to develop a meaningful and
feasible M&E framework for these CABs.

METHODS

Theoretical Background

The development of a framework for CABs is supported
by the patient engagement monitoring and evaluation
(PEME) framework,22 which can be tailored — in cocreation with all stakeholders — to a specific initiative.
The starting point is developing a theory of change
model to collaboratively explain the steps toward the
overarching objectives of the initiative, the relationships
between these steps, and the underlying assumptions and
context factors of how and why an initiative works.23-25
Iteratively, quantitative or qualitative metrics (sometimes
referred to as “indicators” or “measures”) linked to the
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steps of the theory of change are identified and prioritized.
Through discussion, the processes influencing success are
described and illustrated, and consensus may be reached
on a visual narrative model of the steps toward impact,
accompanied by relevant metrics.26
The model and metrics form the tailored framework,
which is structured along 6 components: 1) objectives,
2) input, 3) activities/process, 4) learnings and changes,
5) impacts, and 6) context (Figure 1).22 Hence, the PEME
framework focuses on generative causation to ensure that
M&E stimulates reflection on how and why impacts are
achieved, thereby inspiring change.27,28
Setting

The study was conducted as part of the Patients Active
in Research And Dialogue for an Improved Generation
of Medicines (PARADIGM) consortium. The EuroCAB
program was one of the case studies in this consortium.
Currently, 5 CABs participate in the program: Duchenne
Muscular Dystrophy, Cystic Fibrosis, Cystinosis,
Lymphomas, and Hereditary Haemorrhagic Telangiectasia.
CAB members and industry representatives collaboratively
organize the CAB meetings, which strive for sustainable
partnership that influences R&D decision-making by
focusing on collective thinking and knowledge exchange
between patient communities and researchers. The
EuroCAB program applied and tailored a preliminary
version of the PEME framework22 to develop an M&E
framework for CABs in the rare disease context.
Participatory Approach

A participatory approach was adopted for framework
development. This process was based on the principles
of interactive learning and action29 and comprised 4
iterative data collection and analysis phases: 1) initiation
and preparation; 2) collection, exchange, and integration
of information; 3) priority setting; and 4) validation
and planning (Table 1). Research activities took place
between January 2019 and May 2020. The project team
(authors S.E.F. and L.E.V., who gathered and analyzed
the data, and R.C. and F.H., who guided the process and
interpreted findings) held regular meetings to reflect on
the findings, refine the framework, and plan next steps.
Online Appendix A provides an overview of terms and
definitions used throughout this study.
Vrije Universiteit Amsterdam’s ethics review committee
determined that the research proposal complied with the
ethical guidelines of its Faculty of Science.
Recruitment, and Data Collection/Analysis

Phase 1 – Initiation and Preparation: In phase 1, the
project team aimed to understand the context of the
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Figure 1. Patient engagement monitoring and
evaluation (PEME) framework. (Republished
from Vat et al. Evaluation of patient engagement
in medicine development: a multi-stakeholder
framework with metrics. Health Expect.
2021;24:491-506; with permission from John
Wiley & Sons Ltd.)

EuroCAB program and reviewed the existing M&E
practices to develop a preliminary case description.
This was based on document review (CAB description
and agreements, meeting minutes, and feedback tools
developed by EURORDIS) and informal discussions
with the project team.
Phase 2 – Collection, Exchange, and Integration of
Information: In phase 2, reflection sessions with CAB
members and industry representatives were held to
reflect on their objectives, collaboration processes, and
experiences with M&E. The aim of this phase was to
identify meaningful metrics to iteratively develop and
refine a preliminary M&E framework. Participants were
invited to take part via the EuroCAB coordinator (R.C.)
using a convenience sampling method. Participation
was voluntary. Two group reflection sessions (~2 hours)
were held, one with Duchenne Muscular Dystrophy
CAB members (n=11) and one with Cystic Fibrosis
CAB members (n=11). In addition, one-to-one reflection
conversations (~1 hour) were conducted with 4 industry
representatives from different companies and 2 CAB
chairs (from Duchenne Muscular Dystrophy CAB and
Lymphomas CAB). The preliminary framework and
preliminary findings from the feedback tools developed
by EURORDIS were presented and discussed during
a workshop at a EURORDIS event with patients and
companies. Notes were taken for all sessions.
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Phases 1 and 2 – Analysis: During data collection, the
theory of change was drafted and iteratively refined
to develop a detailed representation of the CAB
collaborations. Using the software program ATLAS.ti
(Scientific Software Development GmbH), documents
and notes from phases 1 and 2 were first analyzed
deductively by author S.E.F. based on components of the
PEME framework. Objectives and metrics within these
components were identified via an inductive approach
of open coding (identifying and describing insights),
followed by axial coding (creating subcategories) by S.E.F.
and L.E.V. Identified metrics were linked to the steps in
the theory of change, resulting in a preliminary framework.
Phase 3 – Prioritization: Phase 3 aimed to prioritize the
objectives and metrics identified in phase 2 to develop a set of
meaningful metrics through a priority-setting questionnaire
consisting of three parts: 1) role and experiences; 2) selection
of applicable objectives and ranking of those selected; and
3) selection of up to 5 most relevant metrics across the core
components of PEME (input, activities/process, learnings
and changes, and impact). The impact metrics were divided
into short- and long-term impact based on when they could
be measured — before or after the start of the discussed
study. The questionnaire was reviewed by R.C., F.H., and
one CAB chair. Industry representatives and members of
all CABs were invited to participate in the questionnaire
via the CAB chairs or the CAB coordinator. Participation
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Table 1. Phased Participatory Approach
Stakeholders
involved

Phase

Objective

Methods

Decision-making

Output

1) Initiation and
preparation

To understand the
EuroCAB context
and review existing
M&E practices

Project team

Document
analysis, informal
conversations

Not applicable

Preliminary case
description

2) Collection,
exchange, and
integration of
information

To reflect on the
collaboration
processes and
experiences with
M&E to identify
meaningful metrics
and iteratively
develop and refine
the framework

23 CAB members Reflection
sessions, 2 group
4 industry
sessions, and
representatives
6 one-to-one
Project team
sessions

CAB members’
and industry
representatives’
insights were used
to develop the
theory of change
model and draft a
set of potentially
relevant metrics

Preliminary
framework
consisting of a
theory of change
and tailored set of
possible metrics

3) Priority setting

To prioritize the
24 CAB members Questionnaire
identified objectives 6 industry
and metrics to
representatives
develop a set of
meaningful metrics

CAB members’
and industry
representatives’
rankings were used
to cluster metrics
into groups of low,
medium, and high
priority

Ranking of
most important
objectives and
most relevant
metrics

4) Validation and
planning

To validate the
theory of change
and set of metrics
for M&E and to
gather ideas for
data collection and
reporting

CAB members
and industry
representatives
discussed which
metrics to include
in the tailored
framework and
discussed how
these could be
measured and
reported

Tailored framework
with sets of
metrics and
ideas on how to
implement M&E

3 CAB members
5 industry
representatives
Project team

Digital dialogue
workshop

CAB, community advisory board; EuroCAB, a collection of CABs participating in this European Organisation for Rare
Diseases program; M&E, monitoring and evaluation.

was voluntary. Of the 30 respondents who completed part
1 and 2 of the questionnaire (Table 2), 27 also completed
part 3. Individual responses were anonymous and kept
confidential.

attended were examined. Since industry representatives
had only engaged with the Cystic Fibrosis CAB, their
responses were excluded from the stratification by disease
area to avoid potential bias.

Phase 3 – Analysis: Data from the questionnaire were
analyzed via descriptive statistics using Microsoft
Excel. The weighted average ranking of the objectives
was calculated (rank 1 was assigned a weight of 7, etc).
Unranked objectives were assigned a weight of 0. Metrics
were ranked based on how often they were selected,
resulting in a prioritized list of all metrics. Respondents
could not indicate the relative weight for each of their
priority metrics, so to do justice to the gross prioritization,
clusters of high-, medium-, and low-priority metrics
were created. Trends in prioritization of metrics among
stakeholder roles, disease areas, and number of meetings

Phase 4 – Validation and Planning: In phase 4, a digital
dialogue workshop was held to validate the theory of
change and set of metrics for M&E and gather ideas for
data collection and reporting. The 5 CAB chairs and 5
industry representatives were invited. Three CAB chairs
participated, 2 could not. A summary of the questionnaire
results and the drafted tailored framework were shared
with participants in advance of the workshop. Using
polling tools, participants were asked to what extent
they agreed with the tailored framework and the “highpriority” metrics and about what reporting structures
they preferred, followed by discussion. Postworkshop,
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Table 2. Respondents to Questionnaire in PrioritySetting Phase
Demographicsa

Total

Stakeholder group
CAB member
Industry representative
Total

24
6b
30

Disease-specific CABc
Cystic Fibrosis
Duchenne Muscular Dystrophy
Cystinosis
Hereditary Haemorrhagic Telangiectasia
Total

7
7
6
4
7
24

Number of CAB meetings attended
None (in the planning phase)
≥1
Total

6
24
30

27 of 30 respondents completed part 3 of the questionnaire
(selection of metrics).
a

Industry representative respondents all collaborated with
the Cystic Fibrosis CAB.

access inequalities” and “improve efficiency and speed”
more important. There were also small differences
between disease areas. For example, the Cystic Fibrosis
CAB found “diminish access inequalities” more important
than other CABs did.
Theory of Change

Starting from the objectives, the actions needed to reach
them, underlying assumptions, and context factors were
iteratively mapped to develop a theory of change (Online
Appendix B). Figure 3 shows an example of a theoretical
pathway. The underlying assumptions describe the
conditions that stakeholders deemed necessary for the
proposed steps to take place. Also, several contextual
factors influencing whether objectives of an initiative are
achieved were identified and indicated. Each step in the
theory of change can be evaluated with metrics (indicated
with codes referring to the metrics in Table 3). In Table
3, data collection methods per metric are suggested. The
following section highlights some rationales for selecting
metrics and describe the links between them.

b

Since all industry representative respondents worked with
the Cystic Fibrosis CAB, their responses were excluded
from stratification per disease area.
c

CAB, community advisory board.

detailed notes were used by the project team and coauthors of this article to make final adjustments to the
tailored framework.

RESULTS

The participatory approach resulted in a tailored
framework for the EuroCAB program, including a
theory of change explaining how and why objectives are
reached, 17 high-priority metrics (out of 61 identified),
and a menu of possible long-term impact metrics.
Herein, we describe each part of the tailored framework,
including rationales for metric selection.
Objectives

Seven objectives for the CABs were identified. The
prioritization questionnaire showed that, on average,
CAB members and industry representatives considered
the objective “to ensure products better meet patients’
unmet medical needs” as the most important (Figure 2).
The relative importance of the other objectives differed
somewhat by stakeholder group. For example, industry
ranked “enhance transparency and trust” higher than did
CAB members, whereas CAB members found “diminish
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Metrics

The metric “Feeling of trust between stakeholders” was
selected most often. This metric was categorized under
both activities/process and impact because while some
indicated that improved trust is itself an impact, others
felt that it is more a means to an end, strongly related
to the metric “Feeling of openness and transparency.”
In phase 2, most participants indicated that trust is a
precondition for the sustainable long-term collaborations
and that it takes time to develop:
“The more often you meet a company, you can tell that
they have the feeling that we have important things
to say, and that is exactly what we are trying to give
them. They listen, they respect … they are very, very
respectful of our opinion and how we interact with
them, and that has led to the trust that is absolutely
vital if you are going into confidential information …
and it takes time for a relationship like that to really
materialize.” (CAB chair 1)
The learnings metrics “Industry’s understanding of patients’
unmet needs,” “Degree to which the meeting helped to
inform research goals,” and “Industry’s understanding
of patient-relevant outcomes measures” were considered
indicative of whether patient needs and experiences are
taken into account in R&D processes, aligning closely
to the most important objective. The metric “CAB
members’ understanding of decision-making in health
product R&D” was selected less often. Nevertheless, this
metric was included because mutual knowledge exchange
is considered a key principle of the CABs and should
therefore be assessed from both perspectives.
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Figure 2. Weighted average
ranking of importance of the
objectives. The size of the
circles corresponds to the rank
(1 = most important, 7 = least
important).

To improve industry’s understanding of patient needs
and reach the objectives, it was often emphasized that
the “right” people need to attend the meeting. Therefore,
the metric “Diversity of stakeholders” was included.
Diversity of CAB members ensures that the insights and
recommendations reflect to some extent those of the overall
patient population. Diversity of industry representatives
(eg, in seniority level) indicates the scope of the influence
of CAB members on decision-making, as participants
noted that broad diversity helps to spread awareness and
understanding of patient needs throughout the company.
The metric “Degree to which the collaboration helps to
demonstrate the value of a product to regulators and health
technology assessment bodies” was selected to capture
whether industry representatives report an influence of the
collaboration on decision-making beyond their company.
Moreover, the metrics “Degree to which outcome
measures of a trial are patient-centric” and “Expected
study participant burden” were selected to assess whether
a trial is well designed, both in terms of the quality of
evidence generated and participant experience, as these
topics are often discussed in the meetings and patientcentric design is important to companies seeking to recruit
quickly, minimize and prevent study drop-outs, and finish

Original Research

trials on time. One participant emphasized that, compared
to longer-term impact metrics, the expected burden on
study participants could be relatively easily attributed to
patient engagement, for example, by reducing the number
of hospital visits in a trial. Therefore, this metric was
thought to provide compelling evidence of the value of
engaging patients.
To track whether the changes needed to reach the impacts
are made, more operational metrics, such as “Number
and type of planned or recommended actions and changes
(not) implemented” were selected. Tracking followup after the meeting is essential to ensure progress and
prevent repetition:
“In the end, we completely lost track of everything
because people were not in charge of the same things.
And if there are no clear action steps, and there
weren’t any because of the lack of alignment on the
topics discussed, then it is very challenging [to make
progress].” (CAB chair 3)
Several CAB members pointed out that they would like
to receive more feedback from industry on where change
is (not) happening to help them understand potential
limitations industry may have and reprioritize discussion

aah.org/jpcrr
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Figure 3. Example of a pathway of the theory of change for community advisory boards in the EuroCAB program.
Bright color boxes: actions needed to achieve the objectives. Faded color boxes: underlying assumptions
(conditions deemed necessary for the steps to take place). Light gray box: context factors (external influences).
(A2), (I3), (L5), etc link to that respective metric defined in Table 3. For the full theory of change, see Online
Appendix B. CAB, community advisory board; CM, CAB member; HTA, health technology assessment; IR,
industry representative; R&D, research and development.
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Table 3. Set of Metrics for the Community Advisory Boards (CABs) in EuroCAB
Framework
component
Input

Activities /
process

Learnings and
changes

Short-term
impactc

Metric

Codea

Number of
stakeholders
who selected Suggested data collection
metric (N=27) method

Feeling of preparedness of CAB members and
industry representatives

I1

21

Postmeeting survey
Success tracker

Priorities for the meeting of CAB members and
industry representatives

I2

21

Success tracker

Diversity of CAB members (eg, role within
community, disease subtype, demographics) and
industry representatives (eg, role, department,
seniority level)

I3

18

Postmeeting survey

Quality and timing of preparation materials

I4

15

Postmeeting survey

Feeling of trust between stakeholders

A1

22

Postmeeting survey

Degree to which expectations of the meeting
were met

A2

19

Postmeeting survey

Usefulness of the meeting

A3

18

Postmeeting survey

Feeling of transparency and openness

A4

17

Postmeeting survey

Industry representatives’ understanding of
patients’ unmet needs

L1

21

Postmeeting survey
Annual reflection

Degree to which the meeting helped to inform
research goals of the company

L2

15

Postmeeting survey
Annual reflection

Industry representatives’ understanding of
patient-relevant outcome measures

L3

15

Postmeeting survey
Annual reflection

CAB members’ understanding of decision-making L4
in health product research and development

9b

Postmeeting survey
Annual reflection

Number and type of planned or recommended
actions and changes (not) implemented

L5

14

Success tracker

Feeling of trust between stakeholders

IM1

21

Postmeeting survey
Annual reflection

Degree to which outcome measures of a trial are
patient-centric

IM2

19

Trial protocol review

Expected study participant burden (eg,
convenience of study visits, procedures)

IM3

18

Trial protocol review
Patient-facing material review

Degree to which the collaboration helps to
demonstrate the value of a product to regulators
and health technology assessment bodies

IM4

14

Trial protocol review
Annual reflection

a

Codes link to the steps in the theory of change model (Figure 3, Online Appendix B).

b

This metric was not categorized as high-priority but was included because it supports the idea of shared learning.

In the prioritization questionnaire, impact was split into short- and long-term impact. Participants indicated that it is not
feasible or meaningful for each CAB to measure all high-priority long-term impact metrics derived from the questionnaire.
Therefore, it was proposed to create a “menú” of long-term impact metrics (Table 4). CAB members and industry partners
will make a selection from the menu based on their CAB priorities, capacity, and resources.
c

topics. Likewise, industry representatives indicated that
an open discussion on expectations helps to align concrete
goals and timeframes and prevent disappointment and
frustration:
“It [tracking priorities, discussions, and actions] can
also support the discussion around is it realistic that
an impact can happen on this priority. … If you see
that you keep on hitting a block on certain type of
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topic you can just say: ‘Okay, we agree that we are
not going to make progress here so we can just kind
of focus on other topics.’” (Industry representative 1)
Accordingly, the metric “Stakeholders’ priorities for the
meeting” was selected because it could indicate whether
the most important topics are discussed. True co-creation
of the agenda and thorough preparation were considered
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essential because these create belief in the value and
ownership of engagement among all involved.
It was suggested to exclude the long-term impact metrics
from the set and include them instead in the tailored
framework via a “menu” approach, as presented in
Table 4. Participants indicated that long-term impact
metrics are valuable as aspirational targets, but many
contextual influences may make it difficult to attribute
causality. Measuring long-term impact would therefore
require thorough and continuous tracking of decisions
and changes. The menu allows stakeholders to prioritize,
through dialogue, the most meaningful metric(s) for their
collaboration while ensuring the burden of measurement
remains feasible.

DISCUSSION

In this study, the preliminary PEME framework was
tailored in co-creation with relevant stakeholders to the
context of CABs in the EuroCAB program. The various
information needs shaped the tailored framework. Each
collaboration between patients and industry is unique,
and tailoring M&E by respective context can improve
the relevance of the information collected, enhancing
learning and reflexivity.12,30 Such continuous reflection
is needed to understand under what conditions progress
toward the objectives is made and to develop strategies to
enhance impact.31 On the other hand, standardized M&E
enables data aggregation, generalization, and comparison
with other engagement initiatives, thereby better meeting

accountability purposes.32,33 We aimed to balance these
purposes by tailoring a framework to the CAB method
and rare diseases context while also standardizing a set
of metrics across all CABs in the EuroCAB program,
combining metrics for learning and accountability.
Our results suggest that “input,” “activities/process,”
“learnings and changes,” and “short-term impact” metrics
could be standardized across CABs, while the long-term
impact metrics could best be tailored to the objectives,
capacity, and resources of the collaboration. This resulted
in a combination of fixed and flexible sets of metrics.
In line with earlier studies, the results suggest that
stakeholders’ M&E priorities differ because of varying
interests and needs.11,12,14 In alignment with the CABs’
focus on equal partnership and mutual knowledge
exchange,20 the framework and metrics were constructed
from the perspectives both of CAB members and
industry and will be assessed from both perspectives
when possible. The recognition that the metrics need
to be meaningful for all stakeholders underlines the
importance of tailoring M&E to enhance impact. Some
of the selected metrics are in line with other studies,
such as preparedness,17 diversity of patients,34 the
recommendations (not) implemented and why,35 and
the changes in research questions and design.36 These
metrics might be applicable to patient engagement
initiatives in various contexts. Other metrics may be
particularly relevant in the rare disease context, such as
“Number of patients in preapproval access programs”

Table 4. “Menu” of Long-Term Impact Metrics for EuroCABs

Long-term impact metricsa

Number of
stakeholders who
selected metric
(N=27)

Perceptions on the alignment of research programs with patients’ needs

16

Time until regulatory approval and health technology assessment reimbursement decisions

14

Retention rate (number/percentage of participants retained in a trial and assessed)

14

Patient satisfaction with participation in a trial

13

Quality of a product (eg, drug, technology, service, information materials)

12

Time from start until the end of a trial (first participant in/last participant out)

12

Number of avoidable amendments (often costly changes to a trial protocol as a result of
operational barriers)
Number of patients in a preapproval access program

11

Diversity of participants in a trial (demographics, disease subtype, hard to reach populations, etc)

11

Number of patients who have access to clinical trials

8

Recruitment rate (number of participants recruited per site per month)

7

Reputation of industry within the patient community

6

11

Long-term impact metrics were not coded and indicated in the theory of change, as no consensus was reached and no
methods were discussed.
a
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because of the high unmet medical need. Future studies
could further explore the framework’s generalizability
to other disease contexts outside of rare diseases.
The PEME framework supported the identification of
relevant metrics and ensured that the tailored framework
comprehensively captures the relationship between input
and impacts. This improves understanding of the processes
that influence success and can enable the attribution of
causality.37 However, it remains difficult to prioritize
metrics. The selected metrics do not fully reflect the
potential value of the CABs, as they focus mainly on
R&D while discussed topics and impacts may be broader.
Despite excluding many steps of the theory of change
from assessment, the set of metrics is still ambitious and
implementation may prove challenging. This difficulty
in prioritization could perhaps be overcome by urging
participants to make their selection criteria more explicit
(eg, relevant, feasible, transferable).26,27 It is important to
note that the tailored framework is meant as a flexible tool
for reflection — refined by each CAB/industry relationship
— to enhance the collaboration processes. Next steps
include developing and refining quantitative and qualitative
data collection methods and implementing the evaluation
framework to encourage learning and share impacts.38-40
Strengths and Limitations

During the process, we aimed to integrate stakeholders’
different perspectives while respecting diverse viewpoints
through democratic participation complemented by
discussions on the results. The collaborative approach
created a common language and increased ownership of
the tailored framework, which we see as a strength. It also
supported the “relational work” of aligning expectations
and developing a shared purpose.12,22,30 Thus, this process
is itself an extension of the collaborative nature of the
EuroCAB program.
A limitation was that CAB members and industry
representatives of each of the 5 CABs could not
participate in all phases, and the balance between CAB
members and industry was not always exactly equal.
However, all phases included a mix of perspectives. Also,
the framework’s linear success-oriented structure may be
viewed as narrow because, in reality, patient engagement
has many iterations, setbacks, and unintended
outcomes.38-40 Although the metrics are formulated
neutrally to capture both positive and negative effects,
we acknowledge this approach may limit the flexibility
to adapt to changing needs and circumstances.

CONCLUSIONS

This study describes a tailored framework that could
serve as a starting point for monitoring and evaluating

Original Research

patient engagement initiatives. We recommend adapting
and refining the framework as appropriate to enhance
its relevance to the specific context and encourage
collaborative reflection. Such tailored frameworks can
support learning and demonstration of impact, ultimately
enhancing patient engagement in health product research
and development.
Patient-Friendly Recap
• Community advisory boards (CABs) are created
by patient communities, health organizations, and
industry sponsors to provide a structured way
for disease-specific patient experts to interact
with those involved in medical research and
development.
• Monitoring and evaluating CABs can 1) show
whether their contributions reflect the needs of the
broader patient community, 2) help both industry
and patients achieve their goals, and 3) identify
areas where challenges remain.
• To be meaningful for those involved, CAB
evaluation methods should be jointly created.
Authors of this study identified a core set of data
metrics, supplemented by a “menu” of flexible
optional items, to monitor progress and evaluate
specific impacts of individual CABs.
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